Profile data is unavailable for this security.
About the company
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
- Revenue in USD (TTM)23.22bn
- Net income in USD2.86bn
- Incorporated1946
- Employees53.00k
- LocationStryker Corp1941 STRYKER WAYPORTAGE 49002United StatesUSA
- Phone+1 (269) 385-2600
- Fax+1 (269) 385-1062
- Websitehttps://www.stryker.com/
Mergers & acquisitions
| Acquired company | SYK:NYQ since announced | Transaction value |
|---|---|---|
| Inari Medical Inc | 7.71% | 4.89bn |
| NICO Corp | 6.67% | -- |
| Vertos Medical Inc | 12.76% | -- |
| care.ai Inc | 18.78% | -- |
| MOLLI Surgical Inc | 17.92% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medtronic PLC | 33.54bn | 4.66bn | 114.71bn | 95.00k | 24.76 | 2.39 | 15.19 | 3.42 | 3.62 | 3.62 | 26.01 | 37.46 | 0.3692 | 2.17 | 5.31 | 353,021.10 | 5.16 | 4.55 | 5.95 | 5.15 | 65.39 | 66.25 | 13.99 | 13.07 | 1.42 | 11.19 | 0.3714 | 84.20 | 3.62 | 3.01 | 26.82 | -0.2723 | 8.91 | 5.33 |
| Danaher Corp | 23.82bn | 3.77bn | 139.41bn | 61.00k | 37.77 | 2.74 | 22.77 | 5.85 | 5.16 | 5.16 | 32.62 | 71.06 | 0.2931 | 3.70 | 6.92 | 390,491.80 | 4.63 | 5.91 | 5.09 | 6.54 | 59.80 | 59.40 | 15.81 | 19.38 | 1.05 | 15.55 | 0.2447 | 14.68 | -0.0628 | 5.92 | -7.17 | 10.53 | 16.98 | 9.40 |
| Stryker Corp | 23.22bn | 2.86bn | 148.62bn | 53.00k | 52.48 | 7.10 | 37.90 | 6.40 | 7.41 | 7.41 | 60.17 | 54.78 | 0.5437 | 1.62 | 6.25 | 438,075.50 | 6.69 | 6.64 | 8.11 | 7.94 | 64.57 | 63.83 | 12.31 | 13.02 | 0.9985 | -- | 0.445 | 44.01 | 10.23 | 8.71 | -5.43 | 7.52 | 3.07 | 9.27 |
| Boston Scientific Corp | 17.55bn | 2.03bn | 154.82bn | 53.00k | 76.71 | 6.97 | 46.69 | 8.82 | 1.36 | 1.36 | 11.79 | 15.02 | 0.4571 | 2.02 | 7.03 | 331,188.70 | 5.27 | 3.08 | 6.10 | 3.57 | 68.73 | 68.51 | 11.54 | 7.78 | 0.8834 | 9.84 | 0.335 | 0.00 | 17.61 | 9.30 | 18.03 | 25.38 | 5.31 | -- |
| Thermo Fisher Scientific Inc | 42.90bn | 6.52bn | 160.43bn | 125.00k | 24.94 | 3.25 | 16.76 | 3.74 | 17.04 | 17.04 | 112.23 | 130.84 | 0.4374 | 4.86 | 4.47 | 343,184.00 | 6.73 | 7.68 | 7.81 | 9.02 | 41.34 | 44.24 | 15.38 | 16.64 | 1.38 | 24.80 | 0.4086 | 7.09 | 0.0513 | 10.92 | 5.67 | 11.33 | 8.62 | 15.48 |
| Intuitive Surgical Inc | 8.71bn | 2.48bn | 185.00bn | 15.64k | 75.71 | 10.81 | 61.15 | 21.23 | 6.82 | 6.82 | 24.01 | 47.73 | 0.4973 | 2.01 | 7.42 | 557,289.90 | 14.23 | 12.31 | 15.61 | 13.71 | 67.09 | 67.30 | 28.62 | 26.11 | 3.97 | -- | 0.00 | 0.00 | 17.24 | 13.27 | 29.18 | 10.98 | 21.16 | -- |
| Abbott Laboratories | 43.11bn | 13.98bn | 209.67bn | 114.00k | 15.05 | -- | 12.51 | 4.86 | 8.01 | 8.01 | 24.67 | -- | -- | -- | -- | 378,149.10 | -- | 10.17 | -- | 12.46 | 56.20 | 56.19 | 32.43 | 18.50 | -- | 49.90 | -- | 44.79 | 4.59 | 5.63 | 134.18 | 30.06 | 6.14 | 11.44 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 31.43m | 8.24% |
| Greenleaf Asset Management, Inc.as of 08 May 2025 | 17.98m | 4.71% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 16.59m | 4.35% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 14.81m | 3.88% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 11.62m | 3.05% |
| Geode Capital Management LLCas of 31 Mar 2025 | 7.31m | 1.92% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 7.31m | 1.92% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 6.86m | 1.80% |
| Fundsmith LLPas of 31 Mar 2025 | 6.86m | 1.80% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 6.57m | 1.72% |
